Clinical Trial Update: Efficacy, Safety, Pharmacokinetics and Immunogenicity Study of Abatacept Administered Intravenously to Treat Active Polyarticular-course Juvenile Idiopathic Arthritis in Japan [Phase 3]

View source ↗

Summary

Phase 3 trial assessing intravenous abatacept for active polyarticular-course juvenile idiopathic arthritis in Japan completed with results posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Juvenile Idiopathic Arthritis

Drugs mentioned

• Abatacept (abatacept)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Juvenile Idiopathic Arthritis | Phase 3 | Status: COMPLETED | Results posted: 2017-01-11